EU/3/11/916

About

On 27 October 2011, orphan designation (EU/3/11/916) was granted by the European Commission to Lipopharma Therapeutics SL, Spain, for 2-hydroxyoleic acid for the treatment of glioma.

Key facts

Active substance
2-Hydroxyoleic acid
Disease / condition
Treatment of glioma
Date of first decision
27/10/2011
Outcome
Positive
EU designation number
EU/3/11/916

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Lipopharma Therapeutics SL
Ctra. de Valldemossa Km. 7,4 – ParcBIT
Incubadora de Empresas de Base Tecnológica
Edificio 17, 2n, Mod. C-8
E07121 - Palma de Mallorca
Spain
Telephone: +34 97 143 9886
Telefax: +34 97 143 9886
E-mail: info@lipopharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating